ES2725881T3 - Nuevos derivados de imidazolidin-2,4-diona - Google Patents

Nuevos derivados de imidazolidin-2,4-diona Download PDF

Info

Publication number
ES2725881T3
ES2725881T3 ES13900705T ES13900705T ES2725881T3 ES 2725881 T3 ES2725881 T3 ES 2725881T3 ES 13900705 T ES13900705 T ES 13900705T ES 13900705 T ES13900705 T ES 13900705T ES 2725881 T3 ES2725881 T3 ES 2725881T3
Authority
ES
Spain
Prior art keywords
trifluoromethyl
dimethyl
phenyl
methylsulfonyl
dioxoimidazolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13900705T
Other languages
English (en)
Spanish (es)
Inventor
Serge Auvin
Christophe Lanco
Oliver Dutruel
Qi Chao
Kaichun Gu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Application granted granted Critical
Publication of ES2725881T3 publication Critical patent/ES2725881T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES13900705T 2013-12-31 2013-12-31 Nuevos derivados de imidazolidin-2,4-diona Active ES2725881T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/091118 WO2015100617A1 (en) 2013-12-31 2013-12-31 Novel imidazolidine-2,4-dione derivatives

Publications (1)

Publication Number Publication Date
ES2725881T3 true ES2725881T3 (es) 2019-09-30

Family

ID=53492968

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13900705T Active ES2725881T3 (es) 2013-12-31 2013-12-31 Nuevos derivados de imidazolidin-2,4-diona

Country Status (7)

Country Link
US (1) US9975880B2 (cg-RX-API-DMAC7.html)
EP (1) EP3089974B1 (cg-RX-API-DMAC7.html)
JP (1) JP6258508B2 (cg-RX-API-DMAC7.html)
CN (1) CN105849101B (cg-RX-API-DMAC7.html)
ES (1) ES2725881T3 (cg-RX-API-DMAC7.html)
RU (1) RU2650678C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015100617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
DE10322108B4 (de) * 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
BRPI0709771B1 (pt) 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
FR2944525B1 (fr) * 2009-04-17 2011-06-24 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament

Also Published As

Publication number Publication date
WO2015100617A1 (en) 2015-07-09
RU2650678C2 (ru) 2018-04-17
JP2017501193A (ja) 2017-01-12
US20160318908A1 (en) 2016-11-03
EP3089974B1 (en) 2019-02-20
RU2016131297A (ru) 2018-02-06
CN105849101B (zh) 2019-02-19
EP3089974A1 (en) 2016-11-09
EP3089974A4 (en) 2017-06-21
US9975880B2 (en) 2018-05-22
CN105849101A (zh) 2016-08-10
JP6258508B2 (ja) 2018-01-10

Similar Documents

Publication Publication Date Title
ES2955132T3 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de EHMT2 y métodos de uso de los mismos
ES2985987T3 (es) Derivado de N-(aza-aril)ciclolactam-1-carboxamida, método de preparación correspondiente y uso del mismo
ES2886887T3 (es) Inhibidor de EGFR y preparación y aplicación del mismo
AU2019342102B2 (en) Compounds for treating certain leukemias
ES2660914T3 (es) Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD
ES2927954T3 (es) Compuestos 2,5-dioxo-azolina N-sustituidos para la utilización en el tratamiento del cáncer
AU2014351413B2 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
JP5808408B2 (ja) フタラジノンケトン誘導体、その製造法および医薬用途
ES2731216T3 (es) Nuevos compuestos
JP2020196726A (ja) Cdk阻害剤としての置換型ヘテロシクリル誘導体
ES2977656T3 (es) Inhibidores de KDM1A para el tratamiento de enfermedades
DK2970332T3 (en) CHEMICAL UNITS
ES2927021T3 (es) Compuestos heteroaromáticos como inhibidores de vanina
ES2968804T3 (es) Derivado de azaarilo, método de preparación del mismo y uso farmacéutico del mismo
KR102432420B1 (ko) (5,6-디하이드로)피리미도[4,5-e]인돌리진
ES2971098T3 (es) Inhibidores de la quinasa 1 que regula la señal de apoptosis y métodos de uso de los mismos
ES2794868T3 (es) Inhibidores de GLS1 para el tratamiento de enfermedades
KR20160133001A (ko) Tnks1 및/또는 tnks2의 억제제로서의 아미도-치환된 아졸 화합물
KR20120089437A (ko) 플라빈 유도체
JP6258508B2 (ja) 新規のイミダゾリジン−2,4−ジオン誘導体
ES2686353T3 (es) Nuevos derivados de imidazolidino-2,4-diona
WO2024077391A1 (en) Thiazolo[5,4-d]pyrimidine compounds, compositions comprising them and uses thereof
HK1230615B (en) Novel imidazolidine-2,4-dione derivatives
BR122023020299A2 (pt) Composto, uso de um composto, composição farmacêutica e processo para preparação de um composto